July 28, 2020 04:46 PM EDTUpdated July 29, 09:00 AM
Amgen dumps early-stage CD38xCD3 bispecific as 3 programs are sidelined by trial setbacks
Five years after Amgen $AMGN agreed to wager up to $1.8 billion on an alliance with Xencor that spotlighted their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
